Stay updated with breaking news from Inflamm regen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem. ....
EOM Pharmaceuticals Announces First Patients Dosed In R1: RESCUE Phase 1/2a Open-label Trial Evaluating EOM613 In Hospitalized COVID-19 Patients With Severe Symptoms In Brazil prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
EOM Pharmaceuticals Announces First Patients Dosed In R1: RESCUE Phase 1/2a Open-label Trial Evaluating EOM613 In Hospitalized COVID-19 Patients With Severe Symptoms In Brazil prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(0) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ( Aptorum Group or Aptorum ), a clinical-stage biopharmaceutical company, through its affiliate, has entered into a material transfer and option agreement ( Agreement ) with Yale University ( Yale ) to evaluate a group of preclinical stage novel immunomodulators. The novel immunomodulators may potentially target autoimmune and oncology diseases, including but not limited to, rheumatoid arthritis, lupus and sclerosis, as well as a variety of cancers, all subject to further preclinical development and testing. Aptorum also obtained an exclusive option to in-license the novel immunomodulators and its affiliated intellectual property rights including its patent rights and know-how, based on licensing terms pursuant to a binding term sheet incorporated into the Agreement. ....